BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 22872743)

  • 1. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF.
    Hall MA; Pinkston KL; Wilganowski N; Robinson H; Ghosh P; Azhdarinia A; Vazquez-Arreguin K; Kolonin AM; Harvey BR; Sevick-Muraca EM
    J Nucl Med; 2012 Sep; 53(9):1427-37. PubMed ID: 22872743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging prostate cancer lymph node metastases with a multimodality contrast agent.
    Hall MA; Kwon S; Robinson H; Lachance PA; Azhdarinia A; Ranganathan R; Price RE; Chan W; Sevick-Muraca EM
    Prostate; 2012 Feb; 72(2):129-46. PubMed ID: 21538422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
    Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
    Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
    Houghton JL; Zeglis BM; Abdel-Atti D; Aggeler R; Sawada R; Agnew BJ; Scholz WW; Lewis JS
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15850-5. PubMed ID: 26668398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
    Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
    J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deglycosylation of mAb by EndoS for improved molecular imaging.
    Gao P; Pinkston KL; Wilganowski N; Robinson H; Azhdarinia A; Zhu B; Sevick-Muraca EM; Harvey BR
    Mol Imaging Biol; 2015 Apr; 17(2):195-203. PubMed ID: 25135058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.
    Schiavina R; Scattoni V; Castellucci P; Picchio M; Corti B; Briganti A; Franceschelli A; Sanguedolce F; Bertaccini A; Farsad M; Giovacchini G; Fanti S; Grigioni WF; Fazio F; Montorsi F; Rigatti P; Martorana G
    Eur Urol; 2008 Aug; 54(2):392-401. PubMed ID: 18456393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases.
    Cai QY; Yu P; Besch-Williford C; Smith CJ; Sieckman GL; Hoffman TJ; Ma L
    Prostate; 2013 Jun; 73(8):842-54. PubMed ID: 23280511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying multimodal contrast agent biological activity using near-infrared flow cytometry.
    Hall MA; Aldrich MB; Azhdarinia A; Lachance PA; Robinson H; Hazen A; Haviland DL; Sevick-Muraca EM
    Contrast Media Mol Imaging; 2012; 7(3):338-45. PubMed ID: 22539404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases.
    Fortuin AS; Deserno WM; Meijer HJ; Jager GJ; Takahashi S; Debats OA; Reske SN; Schick C; Krause BJ; van Oort I; Witjes AJ; Hoogeveen YL; van Lin EN; Barentsz JO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):712-8. PubMed ID: 22417806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer.
    Heidari P; Esfahani SA; Turker NS; Wong G; Wang TC; Rustgi AK; Mahmood U
    J Nucl Med; 2015 Aug; 56(8):1246-51. PubMed ID: 26069303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor margin detection using quantitative NIRF molecular imaging targeting EpCAM validated by far red gene reporter iRFP.
    Zhu B; Wu G; Robinson H; Wilganowski N; Hall MA; Ghosh SC; Pinkston KL; Azhdarinia A; Harvey BR; Sevick-Muraca EM
    Mol Imaging Biol; 2013 Oct; 15(5):560-8. PubMed ID: 23619897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine-poor region-specific EpCAM monoclonal antibody recognizing native tumor cells with high sensitivity.
    Takao M; Nagai Y; Torii T
    Monoclon Antib Immunodiagn Immunother; 2013 Apr; 32(2):73-80. PubMed ID: 23607341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.
    Van den Bergh L; Lerut E; Haustermans K; Deroose CM; Oyen R; Isebaert S; Budiharto T; Ameye F; Mottaghy FM; Bogaerts K; Van Poppel H; Joniau S
    Urol Oncol; 2015 Mar; 33(3):109.e23-31. PubMed ID: 25655681
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.